Cofoe Medical Technology Co.,Ltd. (SHE:301087)
China · Delayed Price · Currency is CNY 54.35
+0.77 (1.44%)
At close: Aug 4, 2026
Cofoe Medical Technology Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 11,776 | 9,077 | 7,192 | 7,791 | 7,606 | 12,626 | |
Market Cap Growth | 50.81% | 26.21% | -7.68% | 2.43% | -39.76% | - |
Enterprise Value | 10,162 | 7,572 | 5,460 | 5,861 | 5,337 | 12,682 |
Last Close Price | 53.58 | 43.74 | 32.89 | 33.57 | 31.52 | 50.78 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 28.48 | 24.43 | 23.07 | 30.64 | 25.21 | 29.44 |
Forward PE | 25.35 | 21.45 | - | - | - | - |
PS Ratio | 3.22 | 2.68 | 2.41 | 2.73 | 2.56 | 5.55 |
PB Ratio | 2.47 | 1.85 | 1.50 | 1.59 | 1.51 | 2.54 |
P/TBV Ratio | 2.88 | 2.15 | 1.71 | 1.76 | 1.68 | 2.69 |
P/FCF Ratio | 21.59 | 17.54 | 13.25 | 378.22 | - | - |
P/OCF Ratio | 17.11 | 13.05 | 10.84 | 19.78 | 76.89 | 52.61 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 2.78 | 2.24 | 1.83 | 2.05 | 1.79 | 5.57 |
EV/EBITDA Ratio | 18.87 | 16.87 | 13.26 | 19.94 | 18.26 | 28.20 |
EV/EBIT Ratio | 28.73 | 22.64 | 17.65 | 27.87 | 21.24 | 30.13 |
EV/FCF Ratio | 18.63 | 14.63 | 10.06 | 284.55 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.21 | 0.17 | 0.19 | 0.13 | 0.09 | 0.05 |
Debt / EBITDA Ratio | 1.90 | 1.60 | 1.92 | 1.85 | 1.32 | 0.48 |
Debt / FCF Ratio | 1.87 | 1.60 | 1.66 | 31.11 | - | - |
Net Debt / Equity Ratio | -0.35 | -0.33 | -0.36 | -0.36 | -0.44 | -0.66 |
Net Debt / EBITDA Ratio | -3.50 | -3.59 | -4.21 | -6.05 | -7.63 | -7.32 |
Net Debt / FCF Ratio | -3.02 | -3.11 | -3.19 | -86.41 | 4.12 | 12.05 |
Asset Turnover | 0.55 | 0.52 | 0.47 | 0.45 | 0.49 | 0.60 |
Inventory Turnover | 2.62 | 2.42 | 2.27 | 2.87 | 3.64 | 2.94 |
Quick Ratio | 1.59 | 1.85 | 2.27 | 2.70 | 2.83 | 5.74 |
Current Ratio | 2.07 | 2.41 | 2.88 | 3.53 | 3.54 | 6.62 |
Return on Equity (ROE) | 7.98% | 7.63% | 6.43% | 5.09% | 6.04% | 14.40% |
Return on Assets (ROA) | 3.32% | 3.20% | 3.05% | 2.08% | 2.57% | 6.92% |
Return on Invested Capital (ROIC) | 9.57% | 9.15% | 8.38% | 6.28% | 10.14% | 29.58% |
Return on Capital Employed (ROCE) | 7.20% | 6.60% | 6.10% | 4.10% | 4.80% | 8.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 3.29% | 4.09% | 4.33% | 3.26% | 3.97% | 3.40% |
FCF Yield | 4.63% | 5.70% | 7.55% | 0.26% | -7.11% | -2.16% |
Dividend Yield | 3.36% | 4.12% | 5.47% | 3.57% | 3.81% | 2.42% |
Payout Ratio | 95.85% | 100.05% | 120.12% | 98.28% | 86.05% | 0.63% |
Buyback Yield / Dilution | 0.09% | 0.20% | -0.46% | 1.70% | -26.56% | -5.47% |
Total Shareholder Return | 3.45% | 4.31% | 5.01% | 5.28% | -22.75% | -3.04% |